

Deepak Cyril D'souza

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11007890/publications.pdf>

Version: 2024-02-01

76
papers

5,766
citations

117625

34
h-index

98798

67
g-index

78
all docs

78
docs citations

78
times ranked

5509
citing authors

#	ARTICLE	IF	CITATIONS
1	mTORC1 inhibitor effects on rapid ketamine-induced reductions in suicidal ideation in patients with treatment-resistant depression. <i>Journal of Affective Disorders</i> , 2022, 303, 91-97.	4.1	22
2	Cannabis and Psychosis: Recent Epidemiological Findings Continuing the "Causality Debate". <i>American Journal of Psychiatry</i> , 2022, 179, 8-10.	7.2	17
3	Timing of cannabis exposure relative to prodrome and psychosis onset in a community-based first episode psychosis sample. <i>Journal of Psychiatric Research</i> , 2022, 147, 248-253.	3.1	4
4	Consensus paper of the WFSBP task force on cannabis, cannabinoids and psychosis. <i>World Journal of Biological Psychiatry</i> , 2022, 23, 719-742.	2.6	40
5	Sex differences in the acute effects of intravenous (IV) delta-9 tetrahydrocannabinol (THC). <i>Psychopharmacology</i> , 2022, , 1.	3.1	4
6	Psychedelics: Old trips, new destinations in psychopharmacology research. <i>Psychopharmacology</i> , 2022, , 1.	3.1	0
7	Preliminary in vivo evidence of lower hippocampal synaptic density in cannabis use disorder. <i>Molecular Psychiatry</i> , 2021, 26, 3192-3200.	7.9	32
8	Simplified Quantification of ¹¹ C-UCB-J PET Evaluated in a Large Human Cohort. <i>Journal of Nuclear Medicine</i> , 2021, 62, 418-421.	5.0	19
9	Psychosocial and pharmacological treatments for cannabis use disorder and mental health comorbidities: a narrative review. <i>Psychological Medicine</i> , 2021, 51, 353-364.	4.5	17
10	Exocannabinoids, Endocannabinoids, and Psychosis. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2021, 6, 600-602.	1.5	0
11	Differential Cognitive Performance in Females and Males with Regular Cannabis Use. <i>Journal of the International Neuropsychological Society</i> , 2021, 27, 570-580.	1.8	6
12	Identifying brain networks in synaptic density PET (¹¹ C-UCB-J) with independent component analysis. <i>NeuroImage</i> , 2021, 237, 118167.	4.2	18
13	Characterizing psychosis-relevant phenomena and cognitive function in a unique population with isolated, chronic and very heavy cannabis exposure. <i>Psychological Medicine</i> , 2020, 50, 2452-2459.	4.5	8
14	In vivo 5-HT ₆ and 5-HT _{2A} receptor availability in antipsychotic treated schizophrenia patients vs. unmedicated healthy humans measured with [¹¹ C]GSK215083 PET. <i>Psychiatry Research - Neuroimaging</i> , 2020, 295, 111007.	1.8	17
15	The state of clinical outcome assessments for cannabis use disorder clinical trials: A review and research agenda. <i>Drug and Alcohol Dependence</i> , 2020, 212, 107993.	3.2	49
16	Psychosis-Relevant Effects of Intravenous Delta-9-Tetrahydrocannabinol: A Mega Analysis of Individual Participant-Data from Human Laboratory Studies. <i>International Journal of Neuropsychopharmacology</i> , 2020, 23, 559-570.	2.1	23
17	Association of Ketamine With Psychiatric Symptoms and Implications for Its Therapeutic Use and for Understanding Schizophrenia. <i>JAMA Network Open</i> , 2020, 3, e204693.	5.9	103
18	Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis. <i>Lancet Psychiatry</i> , 2020, 7, 344-353.	7.4	147

#	ARTICLE	IF	CITATIONS
19	Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin. <i>Neuropsychopharmacology</i> , 2020, 45, 990-997.	5.4	127
20	Cannabis in psychiatric disorders: the cart before the horse?. <i>Lancet Psychiatry</i> , 2019, 6, 968-969.	7.4	2
21	Test-retest reliability of time-frequency measures of auditory steady-state responses in patients with schizophrenia and healthy controls. <i>NeuroImage: Clinical</i> , 2019, 23, 101878.	2.7	31
22	Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial. <i>Lancet Psychiatry</i> , 2019, 6, 35-45.	7.4	125
23	Age-Related Change in 5-HT ₆ Receptor Availability in Healthy Male Volunteers Measured with ¹¹ C-GSK215083 PET. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1445-1450.	5.0	34
24	Dose-Related Target Occupancy and Effects on Circuitry, Behavior, and Neuroplasticity of the Glycine Transporter-1 Inhibitor PF-03463275 in Healthy and Schizophrenia Subjects. <i>Biological Psychiatry</i> , 2018, 84, 413-421.	1.3	43
25	Minimal effects of prolonged smoking abstinence or resumption on cognitive performance challenge the "self-medication" hypothesis in schizophrenia. <i>Schizophrenia Research</i> , 2018, 194, 62-69.	2.0	26
26	Tetrahydrocannabinol (THC) impairs encoding but not retrieval of verbal information. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017, 79, 176-183.	4.8	27
27	Feasibility and success of cell-phone assisted remote observation of medication adherence (CAROMA) in clinical trials. <i>Drug and Alcohol Dependence</i> , 2016, 163, 24-30.	3.2	23
28	Reduced Brain Cannabinoid Receptor Availability in Schizophrenia. <i>Biological Psychiatry</i> , 2016, 79, 997-1005.	1.3	83
29	Rapid Changes in Cannabinoid 1 Receptor Availability in Cannabis-Dependent Male Subjects After Abstinence From Cannabis. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2016, 1, 60-67.	1.5	135
30	Human Laboratory Studies on Cannabinoids and Psychosis. <i>Biological Psychiatry</i> , 2016, 79, 526-538.	1.3	113
31	Marijuana and Madness: Associations Between Cannabinoids and Psychosis. <i>Biological Psychiatry</i> , 2016, 79, 511-513.	1.3	13
32	The early identification of psychosis: can lessons be learnt from cardiac stress testing?. <i>Psychopharmacology</i> , 2016, 233, 19-37.	3.1	5
33	Marijuana Legalization: Impact on Physicians and Public Health. <i>Annual Review of Medicine</i> , 2016, 67, 453-466.	12.2	147
34	A Systematic Review of the Evidence for Medical Marijuana in Psychiatric Indications. <i>Journal of Clinical Psychiatry</i> , 2016, 77, 1050-1064.	2.2	63
35	GABA Deficits Enhance the Psychotomimetic Effects of ⁹ -THC. <i>Neuropsychopharmacology</i> , 2015, 40, 2047-2056.	5.4	29
36	⁹ -THC Disrupts Gamma (̳)-Band Neural Oscillations in Humans. <i>Neuropsychopharmacology</i> , 2015, 40, 2124-2134.	5.4	57

#	ARTICLE	IF	CITATIONS
37	Medical Marijuana. JAMA - Journal of the American Medical Association, 2015, 313, 2431.	7.4	75
38	Role of GABA Deficit in Sensitivity to the Psychotomimetic Effects of Amphetamine. Neuropsychopharmacology, 2015, 40, 2822-2831.	5.4	6
39	The Psychosis-like Effects of δ^9 -Tetrahydrocannabinol Are Associated With Increased Cortical Noise in Healthy Humans. Biological Psychiatry, 2015, 78, 805-813.	1.3	44
40	Effects of Nicotine on the Neurophysiological and Behavioral Effects of Ketamine in Humans. Frontiers in Psychiatry, 2014, 5, 3.	2.6	34
41	Gone to Pot - A Review of the Association between Cannabis and Psychosis. Frontiers in Psychiatry, 2014, 5, 54.	2.6	235
42	Problems With the Medicalization of Marijuana. JAMA - Journal of the American Medical Association, 2014, 311, 2377.	7.4	40
43	Effects of δ^9 -tetrahydrocannabinol in individuals with a familial vulnerability to alcoholism. Psychopharmacology, 2014, 231, 2385-2393.	3.1	7
44	Impact of Cannabis Use on the Development of Psychotic Disorders. Current Addiction Reports, 2014, 1, 115-128.	3.4	109
45	Spicing things up: synthetic cannabinoids. Psychopharmacology, 2013, 228, 525-540.	3.1	241
46	Pilot study of Intravenous Nicotine Effects on Cognitive Performance in Schizophrenia. Schizophrenia Research, 2013, 150, 323-324.	2.0	4
47	Glycine Transporter Inhibitor Attenuates the Psychotomimetic Effects of Ketamine in Healthy Males: Preliminary Evidence. Neuropsychopharmacology, 2012, 37, 1036-1046.	5.4	58
48	Dose-Related Modulation of Event-Related Potentials to Novel and Target Stimuli by Intravenous δ^9 -THC in Humans. Neuropsychopharmacology, 2012, 37, 1632-1646.	5.4	89
49	Lower α^2 -Nicotinic Acetylcholine Receptor Availability in Smokers With Schizophrenia. American Journal of Psychiatry, 2012, 169, 326-334.	7.2	59
50	Dose-Related Behavioral, Subjective, Endocrine, and Psychophysiological Effects of the μ Opioid Agonist Salvinorin A in Humans. Biological Psychiatry, 2012, 72, 871-879.	1.3	106
51	Cannabinoids, Working Memory, and Schizophrenia. Biological Psychiatry, 2012, 71, 662-663.	1.3	4
52	Nicotine Fails to Attenuate Ketamine-Induced Cognitive Deficits and Negative and Positive Symptoms in Humans: Implications for Schizophrenia. Biological Psychiatry, 2012, 72, 785-794.	1.3	36
53	The safety of studies with intravenous δ^9 -tetrahydrocannabinol in humans, with case histories. Psychopharmacology, 2012, 219, 885-896.	3.1	29
54	Cannabis, endocannabinoids and neurodevelopment. , 2011, , 66-81.		2

#	ARTICLE	IF	CITATIONS
55	Cannabis and cognition: short- and long-term effects. , 2011, , 91-102.		15
56	Does cannabis cause lasting brain damage?. , 2011, , 103-113.		3
57	Probing GABA Receptor Function in Schizophrenia with Iomazenil. <i>Neuropsychopharmacology</i> , 2011, 36, 677-683.	5.4	34
58	Efeitos comportamentais, cognitivos e psicofisiológicos dos canabinoides: relevância para a psicose e a esquizofrenia. <i>Revista Brasileira De Psiquiatria</i> , 2010, 32, 515-530.	1.7	27
59	Cannabinoids and psychosis. <i>International Review of Psychiatry</i> , 2009, 21, 152-162.	2.8	68
60	Cannabis and psychosis/schizophrenia: human studies. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2009, 259, 413-431.	3.2	221
61	Preliminary evidence of cannabinoid effects on brain-derived neurotrophic factor (BDNF) levels in humans. <i>Psychopharmacology</i> , 2009, 202, 569-578.	3.1	102
62	The effects of cannabinoids on serum cortisol and prolactin in humans. <i>Psychopharmacology</i> , 2009, 203, 737-744.	3.1	95
63	Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Δ^9 -tetrahydrocannabinol in humans. <i>Psychopharmacology</i> , 2008, 198, 587-603.	3.1	105
64	Blunted Psychotomimetic and Amnesic Effects of Δ^9 -Tetrahydrocannabinol in Frequent Users of Cannabis. <i>Neuropsychopharmacology</i> , 2008, 33, 2505-2516.	5.4	225
65	Cannabinoids and Psychosis. <i>International Review of Neurobiology</i> , 2007, 78, 289-326.	2.0	83
66	γ -Aminobutyric Acid-Serotonin Interactions in Healthy Men: Implications for Network Models of Psychosis and Dissociation. <i>Biological Psychiatry</i> , 2006, 59, 128-137.	1.3	32
67	Greater vulnerability to the amnesic effects of ketamine in males. <i>Psychopharmacology</i> , 2006, 187, 405-414.	3.1	43
68	The acute effects of cannabinoids on memory in humans: a review. <i>Psychopharmacology</i> , 2006, 188, 425-444.	3.1	441
69	Potentiation of Low Dose Ketamine Effects by Naltrexone: Potential Implications for the Pharmacotherapy of Alcoholism. <i>Neuropsychopharmacology</i> , 2006, 31, 1793-1800.	5.4	48
70	Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction. <i>Biological Psychiatry</i> , 2005, 57, 594-608.	1.3	524
71	The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis. <i>Neuropsychopharmacology</i> , 2004, 29, 1558-1572.	5.4	895
72	Cannabinoids and the cerebellum: a potential role in the development of psychosis. , 0, , 144-159.		1

#	ARTICLE	IF	CITATIONS
73	The neural basis for the acute effects of cannabis on learning and psychosis. , 0 , 160-168.		1
74	Does cannabis use cause schizophrenia? The epidemiological evidence. , 0 , 169-183.		0
75	Postmortem studies of the brain cannabinoid system in schizophrenia. , 0 , 184-192.		0
76	The acute effects of cannabinoids in patients with psychotic illness. , 0 , 198-209.		0